<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013543</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-014</org_study_id>
    <nct_id>NCT03013543</nct_id>
  </id_info>
  <brief_title>Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity</brief_title>
  <official_title>Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhythm Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhythm Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight,
      hunger assessments and other factors in patients with rare genetic disorders of obesity,
      including POMC deficiency, LepR deficiency, Bardet-Biedl syndrome and Alström syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Setmelanotide on Body Weight Reduction</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients in each subgroup of RGDO who achieve at least 5% body weight reduction from baseline, at ~3 months treatment with setmelanotide.genetic mutations.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic)</condition>
  <condition>Leptin Receptor Deficiency Obesity</condition>
  <condition>Bardet-Biedl Syndrome</condition>
  <condition>Alstrom Syndrome</condition>
  <condition>Smith-Magenis Syndrome</condition>
  <arm_group>
    <arm_group_label>Setmelanotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Setmelanotide subcutaneous injection once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Setmelanotide</intervention_name>
    <description>RM-493 once daily subcutaneous injection</description>
    <arm_group_label>Setmelanotide</arm_group_label>
    <other_name>RM-493</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with the following genotypes and/or clinical assessment:

               1. POMC/PCSK1/LEPR heterozygous

               2. POMC/PCSK1/LEPR compound heterozygous (two different mutations in gene) or
                  homozygous deficiency obesity

               3. POMC/PCSK1/LEPR composite heterozygous (two or more mutations in two or more
                  genes) deficiency obesity

               4. Smith-Magenis Syndrome (SMS)

               5. SH2B1 deficiency obesity

               6. Chromosomal rearrangement of the 16p11.2 locus causing obesity

               7. CPE compound heterozygous or homozygous deficiency obesity

               8. Leptin deficiency obesity with loss of response to metreleptin

               9. SRC1 deficiency obesity

              10. MC4R deficiency obesity Note: The specific genotype for all patients must be
                  reviewed by the Sponsor prior to study enrollment to confirm that the patient
                  meets Inclusion Criterion #1. In addition, enrollment of patients in some
                  subgroups may be prioritized by the Sponsor in order to ensure enrollment of
                  patients with (1) well described, loss-of-function genetic mutations, (2) a
                  variety of genetic variants, or (3) genetic variants likely to respond to
                  setmelanotide.

          2. Age 6 years and above.

          3. Obese, defined as Body Mass Index (BMI) ≥ 30 kg/m2 for patients ≥16 years of age or
             BMI≥ 95th percentile for age and gender for patients 6 up to 16 years of age.

          4. Study participant and/or parent or guardian is able to communicate well with the
             Investigator, to understand and comply with the requirements of the study, and is able
             to understand and sign the written informed consent/assent.

          5. Female participants of child-bearing potential must be confirmed non-pregnant, and
             agree to use contraception as outlined in the protocol. Female participants of
             non-childbearing potential, defined as surgically sterile (status post hysterectomy,
             bilateral oophorectomy, or bilateral tubal ligation), post-menopausal for at least 12
             months (and confirmed with a screening Follicle-Stimulating Hormone [FSH] level in the
             post-menopausal lab range), and failure to have achieved menarche, do not require
             contraception during the study.

          6. Male participants with female partners of childbearing potential must agree to a
             doublebarrier method if they become sexually active during the study. Male patients
             must not donate sperm during and for 90 days following their participation in the
             study.

        Exclusion Criteria:

          1. Recent intensive (within 2 months) diet and/or exercise regimen with or without the
             use of weight loss agents including herbal medications that has resulted in &gt; 2%
             weight loss.

          2. Use of any medication that is approved to treat obesity within three months of first
             dose of study drug (e.g., orlistat, lorcaserin, phentermine-topiramate,
             naltrexone-bupropion). Note:Glucagon-like peptide-1 (GLP-1) receptor agonists may be
             used up to the dose approved for the treatment of diabetes mellitus (e.g., liraglutide
             up to a daily dose of 1.8 mg) as long as (1) is it not being prescribed for the
             treatment of obesity, (2) the dose has been stable for at least three months prior to
             enrollment, (3) the patient has not experienced weight loss during the previous three
             months, AND (4) the patient intends to keep the dose stable throughout the course of
             the study.

          3. Gastric bypass surgery within the previous six months or any prior gastric bypass
             surgery resulting in &gt;10% weight loss durably maintained from the baseline
             pre-operative weight with no evidence of weight regain. Specifically, patients may be
             considered if surgery was not successful, or resulted in &lt;10% weight loss compared to
             pre-operative baseline weight or clear evidence of weight regain after an initial
             response to bariatric surgery. All patients with a history of bariatric surgery must
             be discussed with and receive approval from the Sponsor prior to enrollment.

          4. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other
             psychiatric disorder(s) that the Investigator believes will interfere significantly
             with study compliance.

             Neurocognitive disorders affecting ability to consent will not be disqualifying as
             long as an appropriate guardian able to give consent has been appointed.

          5. A PHQ-9 score of ≥ 15 or any suicidal ideation of type 4 or 5 on the C-SSRS during
             Screening, any lifetime history of a suicide attempt, or any suicidal behavior in the
             last month. Note: Patients who are unable to complete the PHQ-9 or C-SSRS due to
             significant neurocognitive defects may be allowed to enroll in the study, as long as
             in the opinion of the Primary Investigator there are no clinical signs or symptoms of
             suicidal behavior.

          6. Current, clinically significant pulmonary, cardiac, or oncologic disease considered
             severe enough to interfere with the study and/or confound the results. Any patient
             with a potentially clinically significant disease should be reviewed with the Sponsor
             to determine eligibility.

          7. HbA1c &gt;9.0% at Screening

          8. History of significant liver disease or abnormal liver tests on Screening (i.e. &gt; 1.5
             x upper limit of normal [ULN] for alanine transaminase [ALT], aspartate transaminase
             [AST], alkaline phosphatase, or serum bilirubin). Note: Patients entering the study
             with SRC1 haploinsufficiency obesity must be evaluated during the Screening Period for
             hepatic fibrosis by appropriate imaging techniques (e.g., transient elastography or
             magnetic resonance elastography). Any patient with moderate or greater fibrosis (e.g.,
             the equivalent of a METAVIR score ≥ 2) will be excluded from the study. Note: A
             patient with a diagnosis of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic
             steatohepatitis (NASH) may be allowed to enroll in the study, after consultation with
             the Sponsor. Other significant liver disease, such as cirrhosis, are exclusionary.

          9. Glomerular filtration rate (GFR) &lt;30 mL/min at Screening.

         10. History or close family history (parents or siblings) of skin cancer or melanoma (not
             including non-invasive/infiltrative basal or squamous cell lesion), or patient history
             of ocular-cutaneous albinism.

         11. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions
             (excluding non-invasive basal or squamous cell lesion), determined as part of a
             comprehensive skin evaluation performed by a qualified dermatologist during Screening.

             Any concerning lesions identified during the Screening Period will be biopsied and
             results known to be benign prior to enrollment. If the pre-treatment biopsy results
             are of concern, the patient may need to be excluded from the study.

         12. Patient is, in the opinion of the Study Investigator, not suitable to participate in
             the study.

         13. Participation in any clinical study with an investigational drug/device within 3
             months prior to the first day of dosing.

         14. Patients previously enrolled in a clinical study involving setmelanotide or any
             previous exposure to setmelanotide.

         15. Significant hypersensitivity to any excipient in the study drug.

         16. Inability to comply with QD injection regimen.

         17. Females who are breastfeeding or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray Stewart</last_name>
    <role>Study Chair</role>
    <affiliation>Rhythm Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Ohayon</last_name>
    <email>oohayon@rhythmtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Simon Williamson Clinic, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Woodle</last_name>
      <phone>205-870-8803</phone>
      <email>Andrea.Woodle@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>William Kirby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Phoenix Southeast</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Ross</last_name>
      <phone>480-775-1115</phone>
      <email>Caitlin.Ross@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Randall Severance</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Scrivano</last_name>
      <phone>480-751-2490</phone>
      <email>Ruth.Scrivano@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Tami Bruce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Meli</last_name>
      <phone>480-323-1081</phone>
      <email>smeli@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>James Swain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials-Downtown</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials Headquarters</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>San Diego Wake Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Quezon</last_name>
      <phone>619-528-5000</phone>
      <email>jquezon@mccresearch.com</email>
    </contact>
    <investigator>
      <last_name>Laurie Han-Conrad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CU Diabetes and Endocrinology Clinical Trial Program</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vatsala Singh</last_name>
      <phone>720-645-8614</phone>
      <email>vatsala.singh@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Cornier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Davis</last_name>
      <phone>352-294-5280</phone>
      <email>davisca@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AXIS South Florida Clinical Trials</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kory Grench</last_name>
      <phone>407-303-2537</phone>
      <email>Kory.Grench@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Steven Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - St. Petersburg</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Shade</last_name>
      <phone>727-544-6367</phone>
      <email>Kristin.Shade@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Linda Murray</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reuben Martinez</last_name>
      <phone>310-494-2233</phone>
      <email>reuben.martinez@synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Newberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Partners</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Milliard</last_name>
      <phone>207-662-6712</phone>
      <email>millic@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Mike Dedekian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH Hatfield Clinical Research Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlin Ballenger</last_name>
      <phone>301-496-6726</phone>
      <email>kaitlin.ballenger@nih.gov</email>
    </contact>
    <investigator>
      <last_name>Jack A Yanovski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Cobb</last_name>
      <email>Victoria.Cobb@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Rushika Conroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Stubblefield</last_name>
      <phone>314-454-6076</phone>
      <email>hannah.s@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Sprague</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>AXIS New York Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda House</last_name>
      <email>ahouse@upa.chob.edu</email>
    </contact>
    <contact_backup>
      <phone>716-323-0075</phone>
    </contact_backup>
    <investigator>
      <last_name>Indrajit Majumdar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AXIS Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine Albu</last_name>
      <phone>212-241-8655</phone>
      <email>Jeanine.AlbuMD@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Deena Adimoolam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anah Kim</last_name>
      <phone>212-342-4622</phone>
      <email>ak3578@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Wendy Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Layer</last_name>
      <phone>919-684-0625</phone>
      <email>marcus.layer@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Freemark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Jolly</last_name>
      <phone>919-781-2514</phone>
    </contact>
    <investigator>
      <last_name>Wayne Harper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Henry</last_name>
      <phone>330-252-1500</phone>
      <email>Brooke.Henry@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Hull</last_name>
      <phone>513-247-5593</phone>
      <email>Christine.Hull@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Paul Nugent</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Hoskins</last_name>
      <phone>614-294-3854</phone>
      <email>Bridget.Hoskins@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Cathy Greiwe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Obesity Institute, Geisinger Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Yohn</last_name>
      <phone>570-214-1004</phone>
      <email>mmyohn2@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Still, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Primary Care Associates, PC</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Harrison</last_name>
      <phone>864-305-1411</phone>
      <email>Kristina.Harrison@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Erin Cooksey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research TN</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Schon</last_name>
      <phone>423-698-4584</phone>
      <email>cschon@clinsearch-us.com</email>
    </contact>
    <investigator>
      <last_name>Mark McKenzie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Mack</last_name>
    </contact>
    <contact_backup>
      <phone>901-287-6869</phone>
      <email>rmack7@uthsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joan Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-3157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Oates</last_name>
      <phone>615-322-8068</phone>
      <email>bethany.l.oates@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ashley Shoemaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Wilson</last_name>
      <phone>713-798-5689</phone>
      <email>tawilson@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Sisley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Castro-Ochoa</last_name>
      <email>Karla.Castro@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer Bashour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Straw</last_name>
      <phone>210-614-7483</phone>
      <phone_ext>4212</phone_ext>
      <email>Melinda.Straw@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Williams Jennings</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Fritz</last_name>
      <phone>801-213-2600</phone>
      <email>Kayla.Frtiz@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Juliana Simonetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Gangan</last_name>
      <phone>206-987-1758</phone>
      <email>Carlo.Gangan@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Christian Roth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Research Institute</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Putnam</last_name>
      <phone>715-221-7262</phone>
      <email>putnam.lauren@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Robert M Haws, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Lyster</last_name>
      <phone>780-248-1770</phone>
      <email>clyster@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Andrea Haqq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Laviani</last_name>
      <phone>+49 731 500-57401</phone>
      <email>Stephanie.Laviani@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Martin Wabitsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conny Kaal-Alfenaar</last_name>
      <phone>+31 10 7036587</phone>
      <email>c.kaal@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Erica Van den Akker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad Autónoma de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>65 28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Ventosino Pérez</last_name>
      <phone>+34 616 531 224</phone>
      <phone_ext>7351</phone_ext>
      <email>nuria.ventosino@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Jesús Argente</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Angel Martos-Moreno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus Pozo Roman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amalia Tamariz Martell-Moreno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Hernandez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vishy Veeranna</last_name>
      <phone>44 (0) 121 371 6694</phone>
      <email>Vishy.Veeranna@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tarekegn Hiwot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elana Henning</last_name>
      <phone>44 (0)1223 762634</phone>
      <email>eh330@medschl.cam.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lynne Stanley</last_name>
      <phone>44 (0)1223 762634</phone>
      <email>ls824@medschl.cam.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Sadaf Farooqi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Alamshah</last_name>
      <phone>44 (0)203 3136197</phone>
      <email>amin.alamshah@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Aime Boakye</last_name>
      <phone>44 (0)203 31331312</phone>
      <email>aime.boakye@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Tony Goldstone</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Bridges</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>June 14, 2020</last_update_submitted>
  <last_update_submitted_qc>June 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POMC deficiency obesity</keyword>
  <keyword>LepR deficiency obesity</keyword>
  <keyword>Bardet-Biedl syndrome</keyword>
  <keyword>Alström Syndrome</keyword>
  <keyword>Smith-Magenis Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smith-Magenis Syndrome</mesh_term>
    <mesh_term>Bardet-Biedl Syndrome</mesh_term>
    <mesh_term>Laurence-Moon Syndrome</mesh_term>
    <mesh_term>Alstrom Syndrome</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

